$29.99 0.07 (+0.23%)
2/9/2010 4:00 PM

Acorda Therapeutics, Inc. (ACOR)

CAPS Rating: 1 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Current Price $29.99 Mkt Cap $1.14B
Open $30.18 P/E Ratio 0.00
Prev. Close $29.92 Div. (Yield) N/A (N/A)
Daily Range $29.94 - $30.43 Volume 954,133
52-Wk Range $15.52 - $31.78 Avg. Daily Vol. 0

ACOR News and Commentary

Caps

How do you think ACOR will perform vs the S&P 500?

Add Stock to Watchlist

All Members

165 Outperform
95 Underperform
 

All-Star Members

43 Outperform
45 Underperform
 

Wall Street

11 Outperform
3 Underperform
 

Top ACOR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.64)
Submitted March 31, 2009

I'm green thumbing Acorda as one of those win-win situations where I don't know the bottom. Fampridine obviously has too much behind it to be summarily dismissed by the FDA, so I'm counting on the rejection of the NDA submission to be a simple… More

0 Comments | Reply | Report this Post

evillate (< 20)
Submitted June 02, 2008

Big jump is too big. I'll watch it come down

0 Comments | Reply | Report this Post
ACOR VS S&P 500 (SPY)

Fools bullish on ACOR are also bullish on:

Fools bearish on ACOR are also bearish on:

Recent Community Commentary

Read the most recent pitches from members about ACOR.

Recs

0
Member Avatar Johnsora (59.11) Submitted: 1/23/2010 12:19:06 PM : Outperform Start Price: $23.29 ACOR Score: +25.41

The MS drug has finally been approved. A family member who has MS brought to my attention. Their doctor told them about it and has a list of clients ready to get prescriptions once available. I was also told this is the first MS drug that works for all types of MS. Big sales are on the horizon.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar GreatStocks3728 (< 20) Submitted: 1/23/2010 9:16:54 AM : Outperform Start Price: $28.25 ACOR Score: +8.87

Great earnings ahead.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar MichaelinWA (88.27) Submitted: 1/22/2010 8:43:14 AM : Outperform Start Price: $25.71 ACOR Score: +20.23

Pick on upcoming FDA approval

Report this Post 0 Comments | Reply | Permalink
View All 35 Pitches »

Leaderboard

Find the members with the highest scoring picks in ACOR.

Score Leader

Jeffreyw

Jeffreyw (97.69) Score: +263.29

Risky and volatile, there is much promise in the research and great demand in this area for successful therapies to treat spinal injuries, MS and central nervous system disorders.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
ignorant1 67.72 10/2/2006 Outperform 1Y $8.88 +237.73% -14.76% +252.49
kaiseras < 20 10/2/2006 Outperform 3M $8.88 +237.73% -14.76% +252.49
EddieBhai 45.69 9/29/2006 Outperform 1Y $9.27 +223.52% -14.93% +238.45
fool1e7 60.82 9/29/2006 Outperform 3W $9.60 +212.40% -14.98% +227.38
pkurkjian 84.77 9/27/2006 Outperform 3W $10.30 +191.17% -14.70% +205.86
papabearof5 < 20 10/4/2006 Outperform 3W $11.00 +172.64% -15.36% +188.00
stockquoter < 20 9/26/2006 Outperform 1Y $11.09 +170.42% -14.60% +185.02
hamzavi < 20 10/5/2006 Outperform 3M $12.60 +138.02% -15.74% +153.76
benariel < 20 10/6/2006 Outperform NS $13.19 +127.37% -15.62% +142.99
wmatin 67.33 10/9/2006 Outperform 3W $14.92 +101.01% -15.61% +116.62
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackMerriman < 20 10/15/2009 Outperform NS $25.07 +19.63% -1.43% +21.06
TrackRodmanRen < 20 10/12/2009 Underperform NS $17.72 +69.24% -0.61% -69.85
TrackPiperJaff 85.79 8/5/2009 Outperform NS $24.85 +20.68% +6.91% +13.77
TrackLeerinkSwan 92.83 7/2/2009 Outperform NS $24.90 +20.44% +18.22% +2.22
TrackZacks 62.21 4/23/2009 Outperform 3M $21.89 +37.00% +26.90% +10.10 1 Comment
TrackHapoalim 23.78 3/24/2009 Outperform NS $26.70 +12.32% +33.35% -21.03
TrackFTNEquityCa 65.55 3/12/2009 Outperform NS $25.25 +18.77% +49.78% -31.01
TrackRBCCapMkts 86.33 11/7/2008 Outperform NS $20.22 +48.32% +18.28% +30.04
TrackRWBaird 87.00 11/3/2008 Outperform NS $21.13 +44.39% +11.83% +32.56 2/4/2010 @ $30.51
TrackZacks 62.21 6/4/2008 Underperform 3M $30.15 -39.73% -29.35% +10.38 10/8/2008 @ $18.17 1 Comment
TrackIcahn 32.10 9/30/2007 Outperform NS $18.35 +19.67% -4.17% +23.85 12/31/2007 @ $21.96 1 Comment
TrackFortisBank 83.59 6/21/2007 Outperform NS $17.87 +67.82% -25.42% +93.25
TrackBofASec 94.61 6/19/2007 Outperform NS $19.60 +53.01% -25.95% +78.96
TrackDeutscheSec 89.68 4/12/2007 Outperform NS $23.50 +27.62% -21.61% +49.22
TrackFBRCapitalM 79.87 4/11/2007 Outperform NS $21.37 +41.79% -9.07% +50.86 6/23/2008 @ $30.30
TrackMorganJos < 20 2/21/2007 Underperform NS $23.40 +28.16% -21.85% -50.01
TrackJimCramer < 20 10/12/2006 Underperform 3W $17.12 +75.18% -16.78% -91.95
TrackPiperJaff 85.79 9/29/2006 Outperform NS $9.73 +163.62% -30.73% +194.35 7/1/2009 @ $25.65
TrackBofASec 94.61 9/26/2006 Outperform NS $10.09 +131.91% +9.84% +122.07 2/21/2007 @ $23.40
TrackLazardCapit < 20 9/26/2006 Outperform NS $10.09 +197.22% -14.10% +211.33

Featured Broker Partners